NASDAQ · Biotechnology

Oculis Holding AG (OCS) Stock

$7.90 -2.35% NASDAQ: OCS Healthcare

Valuation

MetricValue
Price$7.90
Market Cap$486.55M
P/E Ratio-5.17
P/B Ratio2.02
P/S Ratio1702.08
EPS (TTM)$-1.81
52-Week High$34.48
52-Week Low$7.17
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-42.92%
ROA-31.82%
ROCE-39.20%
Gross Margin-28.89%
Operating Margin-167.41%
Net Margin-188.61%
Debt/Equity0.01
Current Ratio5.92

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$1.0M$0
Operating Profit$-13.0M$-32.0M$-81.0M$-73.0M$-79.0M
Net Profit$-19.0M$-39.0M$-89.0M$-86.0M$-95.0M
EPS$-0.57$-1.18$-2.97$-2.12$-1.81
Op Margin———-10671.1%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$58.0M$37.0M$114.0M$120.0M$236.0M
Total Liabilities$119.0M$135.0M$21.0M$47.0M$40.0M
Cash$46.0M$20.0M$38.0M$28.0M$81.0M
Borrowings$114.0M$123.0M$1.0M$1.0M$2.0M

Latest News

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities GlobeNewswire · Jul 8, 2026 Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference GlobeNewswire · Jul 2, 2026 Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 GlobeNewswire · Jun 11, 2026 Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease GlobeNewswire · Jun 9, 2026 Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference GlobeNewswire · Jun 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-14.0M$-25.0M$-54.0M$-47.0M$-62.0M
Investing Cash Flow$0$-7.0M$-54.0M$-18.0M$-60.0M
Financing Cash Flow$-1.0M$0$-6.0M$1.0M$0
Net Cash Flow$41.0M$-26.0M$19.0M$-11.0M$57.0M
Free Cash Flow$-14.0M$-29.0M$-54.0M$-48.0M$-63.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.09
EV / EBITDA-5.30
FCF Yield-15.97%
Quick Ratio8.35
Interest Coverage-93.99
Return 1Y-36.76%
Return 3Y-5.53%
Return 5Y33.99%

Ownership

Insiders Held3.51%
Institutions Held38.98%
Institutions Float Held40.40%
Institutional HolderSharesReport Date
Eqt Fund Management S.a R.l.5,900,2942026-03-31
Gildi - Lifeyrissjodur2,430,4012026-03-31
Aberdeen Group plc1,746,9462026-03-31
Pivotal bioVenture Partners Investment Advisor, LLC1,680,2832026-03-31
Wellington Management Group, LLP1,345,7282026-03-31

About Oculis Holding AG

Oculis Holding AG is led by CEO Riad Sherif, employs 49 people, headquartered in CH, publicly traded since 2021.

Oculis Holding AG (OCS) stock trades at $7.90 with a market capitalization of $486.55M. The stock is valued at a negative price-to-earnings (P/E) ratio of -5.17, reflecting a net loss over the last twelve months, price-to-book of 2.02, price-to-sales of 1702.08. Over the past 52 weeks the stock has ranged between $7.17 and $34.48, and currently trades 77.1% below its 52-week high.

On profitability, Oculis Holding AG generates a return on equity (ROE) of -42.92% (negative, reflecting a net loss), return on capital employed of -39.20%, an operating margin of -167.41%, a net profit margin of -188.61%.

Oculis Holding AG by the numbers, 2020–2025

Between 2020 and 2025 Oculis Holding AG reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-95.0M.

The most recent net margin is -188.61%. On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-79.0M.

Borrowings fell from $55.0M to $2.0M, cash from operations was $-62.0M in the latest year, positive in 0 of the last 6.

Return on equity has averaged -38.0% over five years, and was -48.5% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Oculis Holding AG (OCS) — frequently asked questions

What is Oculis Holding AG (OCS) stock price today?

Oculis Holding AG (OCS) is currently trading at $7.90, down 2.35% today.

What is OCS P/E ratio?

Oculis Holding AG's P/E ratio is -5.17. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is OCS return on equity (ROE)?

Oculis Holding AG's return on equity (ROE) is -42.92%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Oculis Holding AG's market cap?

Oculis Holding AG has a market capitalization of $486.55M.

Does OCS pay a dividend?

Oculis Holding AG is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does OCS carry?

Oculis Holding AG has a debt-to-equity ratio of 0.01. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is OCS's profit margin?

Oculis Holding AG reports a net profit margin of -188.61% — the share of revenue left after every cost, including tax and interest.

What sector is OCS in?

Oculis Holding AG is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is OCS listed on?

Oculis Holding AG trades on NASDAQ under the ticker OCS.

What is OCS's 52-week range?

Over the last year Oculis Holding AG has traded between $7.17 and $34.48.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens OCS currently matches

On the figures above, Oculis Holding AG passes the filters for 8 of our ready-made screens, among them Small Cap Stocks, Stocks Under $10, Debt Free Stocks Under $100. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Small Cap StocksStocks Under $10Debt Free Stocks Under $100Debt Free StocksStocks Under $100Stocks Under $50Debt to Equity Below 1 StocksHigh Current Ratio Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.